Literature DB >> 24294541

Suicide Gene Therapy for Cancer - Current Strategies.

Paul Zarogoulidis1, Kaid Darwiche, Antonios Sakkas, Lonny Yarmus, Haidong Huang, Qiang Li, Lutz Freitag, Konstantinos Zarogoulidis, Marek Malecki.   

Abstract

Current cancer treatments may create profound iatrogenic outcomes. The adverse effects of these treatments still remain, as the serious problems that practicing physicians have to cope with in clinical practice. Although, non-specific cytotoxic agents constitute an effective treatment modality against cancer cells, they also tend to kill normal, quickly dividing cells. On the other hand, therapies targeting the genome of the tumors are both under investigation, and some others are already streamlined to clinical practice. Several approaches have been investigated in order to find a treatment targeting the cancer cells, while not affecting the normal cells. Suicide gene therapy is a therapeutic strategy, in which cell suicide inducing transgenes are introduced into cancer cells. The two major suicide gene therapeutic strategies currently pursued are: cytosine deaminase/5-fluorocytosine and the herpes simplex virus/ganciclovir. The novel strategies include silencing gene expression, expression of intracellular antibodies blocking cells' vital pathways, and transgenic expression of caspases and DNases. We analyze various elements of cancer cells' suicide inducing strategies including: targets, vectors, and mechanisms. These strategies have been extensively investigated in various types of cancers, while exploring multiple delivery routes including viruses, non-viral vectors, liposomes, nanoparticles, and stem cells. We discuss various stages of streamlining of the suicide gene therapy into clinical oncology as applied to different types of cancer. Moreover, suicide gene therapy is in the center of attention as a strategy preventing cancer from developing in patients participating in the clinical trials of regenerative medicine. In oncology, these clinical trials are aimed at regenerating, with the aid of stem cells, of the patients' organs damaged by pathologic and/or iatrogenic factors. However, the stem cells carry the risk of neoplasmic transformation. We discuss cell suicide inducing strategies aimed at preventing stem cell-originated cancerogenesis.

Entities:  

Keywords:  Cancer; Non-viral vectors; Regenerative medicine; Suicide gene therapy; Transporters; Viral vectors

Year:  2013        PMID: 24294541      PMCID: PMC3842193          DOI: 10.4172/2157-7412.1000139

Source DB:  PubMed          Journal:  J Genet Syndr Gene Ther        ISSN: 2157-7412


  150 in total

1.  Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma.

Authors:  Juergen Voges; Regina Reszka; Axel Gossmann; Claus Dittmar; Raphaela Richter; Guido Garlip; Lutz Kracht; Heinz H Coenen; Volker Sturm; Karl Wienhard; Wolf-Dieter Heiss; Andreas H Jacobs
Journal:  Ann Neurol       Date:  2003-10       Impact factor: 10.422

2.  An HSVtk-mediated local and distant antitumor bystander effect in tumors of head and neck origin in athymic mice.

Authors:  W Bi; Y G Kim; E S Feliciano; L Pavelic; K M Wilson; Z P Pavelic; P J Stambrook
Journal:  Cancer Gene Ther       Date:  1997 Jul-Aug       Impact factor: 5.987

3.  A prospective comparison of the epidemiological and clinical characteristics of pandemic (H1N1) 2009 influenza A virus and seasonal influenza A viruses in Guangzhou, South China in 2009.

Authors:  Zi-feng Yang; Yang-qing Zhan; Rong-chang Chen; Rong Zhou; Yu-tao Wang; Yi Luo; Mei Jiang; Ji-qiang Li; Sheng Qin; Wen-da Guan; Ke-fang Lai; Huan-lian Wen; Zeng-wei Liang; Li Li; Nan-shan Zhong
Journal:  Jpn J Infect Dis       Date:  2012       Impact factor: 1.362

4.  Suicide gene therapy using reducible poly (oligo-D-arginine) for the treatment of spinal cord tumors.

Authors:  Young-Wook Won; Kyung-Min Kim; Sung Su An; Minhyung Lee; Yoon Ha; Yong-Hee Kim
Journal:  Biomaterials       Date:  2011-09-15       Impact factor: 12.479

5.  Local inflammation and devascularization--in vivo mechanisms of the "bystander effect" in VPC-mediated HSV-Tk/GCV gene therapy for human malignant glioma.

Authors:  F W Floeth; N Shand; H Bojar; H B Prisack; J Felsberg; E Neuen-Jacob; A Aulich; K J Burger; W J Bock; F Weber
Journal:  Cancer Gene Ther       Date:  2001-11       Impact factor: 5.987

6.  Reprogramming of human somatic cells to pluripotency with defined factors.

Authors:  In-Hyun Park; Rui Zhao; Jason A West; Akiko Yabuuchi; Hongguang Huo; Tan A Ince; Paul H Lerou; M William Lensch; George Q Daley
Journal:  Nature       Date:  2007-12-23       Impact factor: 49.962

Review 7.  CD44v6: a target for antibody-based cancer therapy.

Authors:  Karl-Heinz Heider; Hartmut Kuthan; Gerd Stehle; Gerd Munzert
Journal:  Cancer Immunol Immunother       Date:  2004-02-05       Impact factor: 6.968

8.  Triple negative breast cancers have a reduced expression of DNA repair genes.

Authors:  Enilze Ribeiro; Monica Ganzinelli; Daniele Andreis; Ramona Bertoni; Roberto Giardini; Stephen B Fox; Massimo Broggini; Alberto Bottini; Vanessa Zanoni; Letizia Bazzola; Chiara Foroni; Daniele Generali; Giovanna Damia
Journal:  PLoS One       Date:  2013-06-25       Impact factor: 3.240

9.  Improved retroviral suicide gene transfer in colon cancer cell lines after cell synchronization with methotrexate.

Authors:  Laetitia Finzi; Aurore Kraemer; Claude Capron; Severine Noullet; Diane Goere; Christophe Penna; Bernard Nordlinger; Josette Legagneux; Jean-Fançois Emile; Robert Malafosse
Journal:  J Exp Clin Cancer Res       Date:  2011-10-04

10.  Construction of a novel vector expressing the fusion suicide gene yCDglyTK and hTERT-shRNA and its antitumor effects.

Authors:  Jia Li; Guiying Zhang; Ting Liu; Huan Gu; Lu Yan; Bolin Chen
Journal:  Exp Ther Med       Date:  2012-06-18       Impact factor: 2.447

View more
  36 in total

1.  Targeted gene therapy of the HSV-TK/hIL-12 fusion gene controlled by the hSLPI gene promoter of human non-small cell lung cancer in vitro.

Authors:  Shuhong Hao; Xiaoyuan Du; Yang Song; Ming Ren; Qiwei Yang; Ao Wang; Qingyu Wang; Haiyue Zhao; Zhenwu Du; Guizhen Zhang
Journal:  Oncol Lett       Date:  2018-03-01       Impact factor: 2.967

2.  A Lentiviral Vector Expressing Desired Gene Only in Transduced Cells: An Approach for Suicide Gene Therapy.

Authors:  Zahra Mohammadi; Laleh Shariati; Hossein Khanahmad; Mahsa Kolahdouz; Fariborz Kianpoor; Jahan Afrooz Ghanbari; Zahra Hejazi; Mansoor Salehi; Parvaneh Nikpour; Mohammad Amin Tabatabaiefar
Journal:  Mol Biotechnol       Date:  2015-09       Impact factor: 2.695

Review 3.  Outlook and future of inner ear therapy.

Authors:  Jenna Devare; Samuel Gubbels; Yehoash Raphael
Journal:  Hear Res       Date:  2018-05-17       Impact factor: 3.208

Review 4.  Targeted polymeric nanoparticles for cancer gene therapy.

Authors:  Jayoung Kim; David R Wilson; Camila G Zamboni; Jordan J Green
Journal:  J Drug Target       Date:  2015-06-10       Impact factor: 5.121

5.  PEG10 Promoter-Driven Expression of Reporter Genes Enables Molecular Imaging of Lethal Prostate Cancer.

Authors:  Mariya Shapovalova; John K Lee; Yingming Li; Donald J Vander Griend; Ilsa M Coleman; Peter S Nelson; Scott M Dehm; Aaron M LeBeau
Journal:  Cancer Res       Date:  2019-09-17       Impact factor: 12.701

6.  Cytotoxic effect of co-expression of human hepatitis A virus 3C protease and bifunctional suicide protein FCU1 genes in a bicistronic vector.

Authors:  Alexey Komissarov; Ilya Demidyuk; Dina Safina; Marina Roschina; Andrey Shubin; Nataliya Lunina; Maria Karaseva; Sergey Kostrov
Journal:  Mol Biol Rep       Date:  2017-07-26       Impact factor: 2.316

7.  Tumor-specific expression of shVEGF and suicide gene as a novel strategy for esophageal cancer therapy.

Authors:  Ting Liu; Hai-Jun Wu; Yu Liang; Xu-Jun Liang; Hui-Chao Huang; Yan-Zhong Zhao; Qing-Chuan Liao; Ya-Qi Chen; Ai-Min Leng; Wei-Jian Yuan; Gui-Ying Zhang; Jie Peng; Yong-Heng Chen
Journal:  World J Gastroenterol       Date:  2016-06-21       Impact factor: 5.742

8.  A double suicide gene system driven by vascular endothelial growth factor promoter selectively kills human hepatocellular carcinoma cells.

Authors:  Kai Wu; Liucheng Yang; Zonghai Huang; Haijun Zhao; Jianjun Wang; Shuai Xu
Journal:  Oncol Lett       Date:  2016-03-22       Impact factor: 2.967

Review 9.  Biodegradable Polymeric Nanoparticles for Therapeutic Cancer Treatments.

Authors:  Johan Karlsson; Hannah J Vaughan; Jordan J Green
Journal:  Annu Rev Chem Biomol Eng       Date:  2018-03-26       Impact factor: 11.059

Review 10.  Prodrugs and prodrug-activated systems in gene therapy.

Authors:  Semira Sheikh; Daniel Ernst; Armand Keating
Journal:  Mol Ther       Date:  2021-04-06       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.